Document:

Exhibit1010

EXECUTION VERSION

SECOND AMENDMENT

This Second Amendment, dated as of March 22, 2013 (this “Amendment”), among SOUTHERN STAR CENTRAL CORP. (the “Borrower”),  ROYAL BANK OF CANADA, as a lender and issuing bank (“RBC”), U.S. BANK, NATIONAL ASSOCIATION, as a  
lender (together with RBC, the “Existing Lenders”), ROYAL BANK OF CANADA, as  
administrative agent (the “Administrative Agent”), and BANK OF AMERICA, N.A., as the New Lender (as defined below). 
WITNESSETH: 

WHEREAS, the Borrower, the Existing Lenders and the Administrative Agent are parties to that certain Revolving Credit Agreement, dated as of July 3, 2012, as amended pursuant to the First Amendment thereto dated as of August 17, 2012 (as further amended from time to time, the “Credit Agreement”); 

WHEREAS, the Borrower has requested that the Credit Agreement be amended to, among other things, (i) increase the aggregate Revolving Commitments thereunder from $65,000,000 to $125,000,000 and (ii) remove the provisions and definitions related to the Borrower’s ability to request incremental commitments described in Section 2.18 thereof; 

WHEREAS, pursuant to the terms hereof, the Existing Lenders shall increase their respective Revolving Commitments pursuant to the terms hereof and Bank of America, N.A. (the “New Lender”) shall provide new Revolving Commitments under the Credit Agreement and will become a party thereto; and 

WHEREAS, the Borrower, the Administrative Agent and the Required Lenders are willing to agree to the requested amendments subject to the provisions of this Amendment. 

NOW, THEREFORE, in consideration of the premises contained herein, the parties hereto agree as follows: 

1.    Amendments to Definitions.
a.  The definitions of  “Increased Facility Activation Date”, “Increased Facility    Activation Notice”, “Increased Facility Closing Date”, “New Lender” and    “New Lender Supplement” in Section 1.1 of the Credit Agreement are hereby    deleted in their entirety. 
b.  The definition of “Revolving Commitment” in Section 1.1 of the Credit 
Agreement is hereby deleted in its entirety and replaced with the following: 
““Revolving Commitment”:  as to any Lender, the obligation of such Lender,  
if any, to make Revolving Loans and participate in Letters of Credit in an  
aggregate principal and/or face amount not to exceed the amount set forth  
under the heading “Revolving Commitment” opposite such Lender’s name on  
Schedule 1.1A or in the Assignment and Assumption pursuant to 

080599-0099-11824-13695084

which such  
Lender became a party hereto, as the same may be changed from time to time  
pursuant to the terms hereof. The amount of the Total Revolving  
Commitments as of the Second Amendment Effective Date is $125,000,000.” 
c.  The following definitions shall be added to Section 1.1 of the Credit    Agreement in proper alphabetical order: 

i.    “Second Amendment”: the Second Amendment to the Credit
Agreement dated as of March 22, 2013, among the Borrower, U.S. Bank, National Association, Royal Bank of Canada, the  
Administrative Agent and Bank of America, N.A. 
ii.     “Second Amendment Effective Date”: the effective date of the 
Second Amendment, which date is March 22, 2013. 
2.    Amendment to Section 2.18.  Section 2.18 of the Credit Agreement is hereby deleted
in its entirety.
3.    Amendment to Section 7.2(m).  Section 7.2(m) of the Credit Agreement is hereby
deleted in its entirety and replaced with the following:
“additional Indebtedness of the Borrower or any of its Restricted Subsidiaries  
in an aggregate principal amount (for the Borrower and all Restricted  
Subsidiaries) not to exceed the sum of (A) the greater of (i) $250,000,000 and 
(ii) 15% of Consolidated Net Tangible Assets as set forth on the most recent 
 
quarterly balance sheet at any one time outstanding minus (B) the aggregate 
 
principal amount of debt outstanding pursuant to Section 7.2(a); and” 
4.     Amendment to Schedule 1.1A. Schedule 1.1A to the Credit Agreement is hereby deleted in its entirety and replaced with the schedule set forth in Annex I. 
5.    Amendments to Exhibits: Exhibits G and H and each reference thereto in the Credit
Agreement is hereby deleted in its entirety.
6.    New Lender.
a.    As a signatory hereto, as of the Amendment Effective Date (as defined
below), the New Lender shall become a Lender under the Credit Agreement  
for all purposes and to the same extent as if originally a party thereto and  
shall be bound by and entitled to the benefits of the Credit Agreement. The  
New Lender shall have a Revolving Commitment in the amount set forth  
under the heading “Revolving Commitment” opposite the New Lender’s  
name in Schedule 1.1A to the Credit Agreement (as amended 

080599-0099-11824-13695084

pursuant to the  
terms hereof). On the Amendment Effective Date, the New Lender shall  
make available to the Administrative Agent its pro rata share of Revolving  
Loans outstanding on such date in accordance with Section 2.2 of the Credit  
Agreement as if the New Lender was party to the Credit Agreement on the  
date such Revolving Loans were originally made and the Administrative  
Agent shall reduce the amount of the outstanding Revolving Loans held by  
each of the Existing Lenders as necessary to achieve a ratable allocation of  
the outstanding Revolving Loans. For the avoidance of doubt, the Borrower  
agrees to indemnify the Existing Lenders in accordance with Section 2.14 of  
the Credit Agreement for any loss incurred by the Existing Lenders in  
connection with the prepayment of the outstanding Revolving Loans  
described in this Section 6(a). 
b.     The New Lender (i) represents and warrants that (A) it has full power and 
authority, and has taken all action necessary, to execute and deliver this 
Amendment and to consummate the transactions contemplated hereby and to  
become a Lender under the Credit Agreement, (B) it satisfies the  
requirements, if any, specified in the Credit Agreement that are required to be  
satisfied by it in order to become a Lender and (C) it has received a copy of 

the Credit Agreement, together with copies of the most recent financial  
statements delivered pursuant to Section 6.1 thereof, and such other  
documents and information as it has deemed appropriate to make its own  
credit analysis and decision to enter into this Amendment on the basis of  
which it has made such analysis and decision independently and without  
reliance on the Administrative Agent or any other Lender and (ii) agrees that 
(A) it will, independently and without reliance on the Administrative Agent  
or any other Lender, and based on such documents and information as it shall  
deem appropriate at the time, continue to make its own credit decisions in  
taking or not taking action under the Loan Documents and (B) it will perform  
in accordance with their terms all of the obligations which by the terms of the  
Loan Documents are required to be performed by it as a Lender. 

080599-0099-11824-13695084

c.  The New Lender’s address for notices for the purposes of the Credit    Agreement is as follows: 
Bank of America, N.A. 
700 Louisiana Street, Houston TX 77002 
Attention: Ronald McKaig, Managing Director-Energy Facsimile: 877-283-7502 
Telephone: 713-247-7237 
7.     Upfront Fee. On the Amendment Effective Date, the Borrower shall pay (or cause to  
be paid) to each of the Existing Lenders and the New Lender, in immediately available funds, a non- 
refundable upfront fee (the “Upfront Fee”) in an amount equal to 50 basis points calculated on the  
aggregate amount of (i) in the case of the Existing Lenders, Revolving Commitments provided by the  
Existing Lenders as of the Amendment Effective Date in excess of Revolving Commitments  
previously provided on the Closing Date and (ii) in the case of the New Lender, Revolving  
Commitments provided by the New Lender under the Credit Agreement as of the Amendment  
Effective Date, the full amount of which shall each be fully earned and payable on the Amendment  
Effective Date and which fee shall be payable in addition to any other fees owing to the Existing  
Lenders under the Credit Agreement. 
8.     Representations and Warranties.  The Borrower and each Loan Party hereby represent and warrant on and as of the Amendment Effective Date that (i) it is legally authorized to enter into  
and has duly executed and delivered this Amendment, (ii) no Default or Event of Default has occurred and is continuing and (iii) each of the representations and warranties of each Loan Party set forth in  
the Loan Documents are true and correct in all material respects (except to the extent any such  
representation or warranty is qualified by “materially”, “Material Adverse Effect” or a similar term, in which case such representation and warranty is true and correct in all respects) on and as of the  
Amendment Effective Date, except to the extent such representations and warranties expressly relate to an earlier date (in which case such representations and warranties were true and correct in all  
material respects (except to the extent any such representation or warranty is qualified by  
“materially”, “Material Adverse Effect” or a similar term, in which case such representation and  
warranty is true and correct in all respects) as of such earlier date). 

9.     Effectiveness of Amendment.  This Amendment shall become effective upon the date on which the following conditions precedent have been satisfied or waived (such date, the  
“Amendment Effective Date”). 
(a)     The Administrative Agent shall have received counterparts to this 
Amendment duly executed by the Borrower, the Required Lenders and the New Lender. 
(b)    At the time of and immediately after giving effect to this Amendment, no
Default or Event of Default shall have occurred and be continuing.

(c)    Each of the Existing Lenders and the New Lender shall have received the

080599-0099-11824-13695084

Upfront Fee payable to them in accordance with Section 7 above. 
(d)     The Administrative Agent shall have received payment for all expenses for 
which invoices have been presented at least one Business Day prior to the Amendment Effective Date (including the reasonable fees and expenses of legal counsel) required to be paid. 
10.     Continuing Effect; No Other Amendments or Consents.  Except as expressly provided  
herein, all of the terms and provisions of the Credit Agreement are and shall remain in full force and  
effect.  Each amendment provided for herein is limited to the specific subsection of the Credit  
Agreement specified herein and shall not constitute a consent, waiver or amendment of, or an  
indication of the Administrative Agent’s or the Lenders’ willingness to consent to any action  
requiring consent under any other provisions of the Credit Agreement or the same subsection for any  
other date or time period. 
11.     Expenses.  The Borrower agrees to pay and reimburse the Administrative Agent for all its reasonable out-of-pocket costs and expenses incurred in connection with the preparation and delivery of this Amendment, including, without limitation, the reasonable fees and disbursements of counsel to the Administrative Agent. 

12.     Successors and Assigns.  This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the parties hereto. 
13.     Counterparts.  This Amendment may be executed in any number of counterparts by the parties hereto (including by facsimile and electronic (e.g. “.pdf”, or “.tif”) transmission), each of which counterparts when so executed shall be an original, but all the counterparts shall together constitute one and the same instrument. 
14.     Interpretation; Capitalized Terms.  This Agreement is a Loan Document for the purposes of the Credit Agreement.  Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Credit Agreement. 
15.    GOVERNING LAW.  THIS AMENDMENT SHALL BE GOVERNED BY, AND
CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF
NEW YORK.
[Signature pages follow.]

080599-0099-11824-13695084

IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed and delivered by their proper and duly authorized officers as of the day and year first above written.

	
					
	 
	 
	 
	SOUTHERN STAR CENTRAL CORP

	 
	 
	 
	 
	 

	 
	 
	 
	By:
	/s/ Susanne W. Harris

	 
	 
	 
	Name:
	Susanne W. Harris

	 
	 
	 
	Title:
	Vice President, Chief Financial Officer and Treasurer

080599-0099-11824-13695084

	
					
	 
	 
	 
	ROYAL BANK OF CANADA, as Administrative Agent

	 
	 
	 
	 
	 

	 
	 
	 
	By:
	/s/ Ann Hurley

	 
	 
	 
	Name:
	Ann Hurley

	 
	 
	 
	Title:
	Manager, Agency

	
					
	 
	 
	 
	ROYAL BANK OF CANADA, as an Existing
Lender and Issuing Bank

	 
	 
	 
	 
	 

	 
	 
	 
	By:
	 

	 
	 
	 
	Name:
	 

	 
	 
	 
	Title:
	 

   

080599-0099-11824-13695084

	
					
	 
	 
	 
	ROYAL BANK OF CANADA, as Administrative Agent

	 
	 
	 
	 
	 

	 
	 
	 
	By:
	 

	 
	 
	 
	Name:
	 

	 
	 
	 
	Title:
	 

	
					
	 
	 
	 
	ROYAL BANK OF CANADA, as an Existing
Lender and Issuing Bank

	 
	 
	 
	 
	 

	 
	 
	 
	By:
	/s/ Don J. McKinnerney

	 
	 
	 
	Name:
	Don J. McKinnerney

	 
	 
	 
	Title:
	Authorized Signatory

080599-0099-11824-13695084

	
					
	 
	 
	 
	U.S. BANK NATIONAL ASSOCIATION, as 
an Existing Lender

	 
	 
	 
	 
	 

	 
	 
	 
	By:
	/s/ Tom E. Booth

	 
	 
	 
	Name:
	Tom E. Booth

	 
	 
	 
	Title:
	Vice President

080599-0099-11824-13695084

	
					
	 
	 
	 
	BANK OF AMERICA, N.A., as the New
Lender

	 
	 
	 
	 
	 

	 
	 
	 
	By:
	/s/ Ronald E. McKaig

	 
	 
	 
	Name:
	Ronald E. McKaig

	 
	 
	 
	Title:
	Managing Director

080599-0099-11824-13695084

Annex I 

Schedule 1.1A

Commitment Amounts of the Lenders

	
		
	Name and Address of Lender
	Revolving
Commitment 

	Royal Bank of Canada
2800 Post Oak Blvd., Suite 3900
Houston, TX 77056
	$52,500,000.00

	U.S. Bank, National Association
700 Frederica Street 
Owensboro, KY 42301
	$27,500,000.00

	Bank of America, N.A.
One Bryant Park, 20th Floor 
New York, NY 10036
	$45,000,000.00

	Total Revolving Commitments
	$125,000,000.00

080599-0099-11824-13695084EX-10.1

Exhibit 10.1

STOCK PURCHASE AGREEMENT

This Stock Purchase Agreement is dated as of March 22, 2013 (this “Agreement”),
between SafeStitch Medical, Inc., a Delaware corporation (the “Company”), and the
purchasers whose names and addresses are set forth on the signature pages hereto (individually, a
“Purchaser” and collectively, the “Purchasers”).

WHEREAS, the Company desires to sell to each Purchaser, and each Purchaser desires to purchase
from the Company, shares of the Company’s common stock, par value $0.001 per share (the “Common
Stock”), and warrants on the terms and subject to the conditions set forth in this Agreement
(the “Transaction”).

NOW, THEREFORE, in consideration of the premises and the mutual covenants contained in this
Agreement and for other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, and intending to be legally bound, the parties agree as follows:

Article 1

Purchase and Sale of Common Stock

1.1 Purchase and Sale of the Shares. Subject to the terms and conditions hereof, the
Company hereby agrees to issue and sell an aggregate of 12,096,000 shares (the “Purchased
Shares”) to the Purchasers at a per share purchase price of $0.25 per share (“Per Share
Purchase Price”) and issue 6,048,000 warrants with a conversion price of $0.33 per share (the
“Warrants,” and with the Purchased Shares, the “Securities”). Each Purchaser
hereby agrees to purchase from the Company the number of shares and warrants set forth on such
Purchaser’s signature page hereto, for an aggregate purchase price equal to the number of shares
purchased by such Purchaser multiplied by the Per Share Purchase Price (the “Purchase
Price”).

1.2 Closing; Deliverables. The closing of the issuance and sale of the Securities
(the “Closing”) shall take place at the Company’s offices in Miami, Florida on March 22,
2013 or as soon as possible thereafter (the “Closing”). At Closing, (A) the Company shall
deliver to each Purchaser a copy of the Company’s instructions to its transfer agent instructing
the transfer agent to deliver one or more stock certificates evidencing the Purchased Shares and a
Warrant Certificate substantially in the form of Exhibit A, inclusive of such restrictive and other
legends as set forth in Section 5.1 hereof, and (B) each Purchaser shall pay to the Company the
Purchase Price by wire transfer of immediately available U.S. funds.

Article 2

Additional Agreements

The Company and each Purchaser shall cooperate and use their respective commercially
reasonable efforts to take or cause to be taken all actions, and do or cause to be done all things,
necessary, proper or advisable under this Agreement and applicable laws and regulations to
consummate and make effective the sale of the Purchased Shares and issuance of the Warrants (the
“Sale”) and the other transactions contemplated by this Agreement as soon as practicable,
including preparing and filing as promptly as practicable all documentation to effect all necessary
applications, notices, petitions, filings and other documents and to obtain as promptly as
practicable all permits, consents, approvals and authorizations necessary or advisable to be
obtained from any third party and/or any governmental entity in order to consummate the sale or any
of the other transactions contemplated by this Agreement.

Article 3

Representations and Warranties of the Company

The Company represents and warrants to the Purchasers as of the date hereof as follows:

3.1 Authorization of Agreements, etc. The execution and delivery by the Company of
this Agreement, the performance by the Company of its obligations hereunder, and the issuance, sale
and delivery of the Securities have been duly authorized by all requisite corporate action and will
not result in any violation of, be in conflict with, or constitute a default under, with or without
the passage of time or the giving of notice: (a) any provision of the Company’s Certificate of
Incorporation, as amended, or Bylaws, as amended; (b) any provision of any judgment, decree or
order to which the Company is a party or by which it is bound; (c) any material contract or
agreement to which the Company is a party or by which it is bound (as defined in Item 601(b)(10) of
Regulation S-K under the Securities Exchange Act of 1934, as amended (the “Exchange Act”));
or (d) any statute, rule or governmental regulation applicable to the Company, except for such
violations, conflicts or defaults as would not individually or in the aggregate have a material
adverse effect on the Company.

3.2 Valid Issuance of Common Stock. The Securities have been duly authorized and,
when issued, sold and delivered in accordance with this Agreement for the consideration expressed
herein will be validly issued, fully paid and nonassessable and will be free and clear of all
liens, charges and encumbrances (collectively, “Encumbrances”) of any nature whatsoever
except for (i) restrictions on transfer under this Agreement and under applicable Federal and state
securities laws and (ii) Encumbrances created by each Purchaser.

3.3 Validity. This Agreement has been duly executed and delivered by the Company and
constitutes the legal, valid and binding obligation of the Company, enforceable in accordance with
its terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium,
and other laws of general application affecting enforcement of creditors’ rights generally, and
(ii) as limited by laws relating to the availability of specific performance, injunctive relief, or
other equitable remedies.

3.4 Brokers and Finders. Neither the Company nor any of its subsidiaries, officers,
directors or employees has employed any broker or finder or incurred any liability for any
brokerage fees, commissions or finders’ fees in connection with the Sale or the other transactions
contemplated by this Agreement.

Article 4

Representations and Warranties of Each Purchaser

Each Purchaser represents and warrants to the Company as of the date hereof as follows:

4.1 Authorization of Agreements, etc. Purchaser has full right, power, authority and capacity
to enter into this Agreement and to consummate the transactions contemplated hereby, and the
execution and delivery by Purchaser of this Agreement and the performance by Purchaser of its
obligations hereunder have been duly authorized by all requisite corporate or other action and will
not result in any violation of, be in conflict with, or constitute a default under, with or without
the passage of time or the giving of notice: (a) any provision of the Purchaser’s organizational
documents as currently in effect (if Purchaser is not a natural person); (b) any provision of any
judgment, decree or order to which Purchaser is a party or by which it is bound; (c) any material
contract or agreement to which the Company is a party or by which it is bound (as defined in Item
601(b)(10) of Regulation S-K under the Exchange Act); or (d) any statute, rule or governmental
regulation applicable to the Company, except for such violations, conflicts or defaults as would
not individually or in the aggregate have a material adverse effect on the Company.

4.2 Validity. This Agreement has been duly executed and delivered by Purchaser and
constitutes the legal, valid and binding obligation of Purchaser, enforceable in accordance with
its terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium,
and other laws of general application affecting enforcement of creditors’ rights generally and (ii)
as limited by laws relating to the availability of specific performance, injunctive relief, or
other equitable remedies.

4.3 Investment Representations.

(a) Purchaser is an “accredited investor” within the meaning of Rule 501 of Regulation D
promulgated under the Securities Act of 1933, as amended (the “Securities Act”), and, if
Purchaser is other than a natural person, was not organized for the specific purpose of acquiring
the Securities;

(b) Purchaser is knowledgeable, sophisticated and experienced in financial and business
matters and has sufficient knowledge and experience in investing in companies similar to the
Company so as to be able to evaluate the risks and merits of its investment in the Company and it
is able financially to bear the risks thereof;

(c) the Securities being purchased by Purchaser hereunder are being acquired for Purchaser’s
own account solely for the purpose of investment and not with a present view to, or for sale in
connection with, any distribution thereof;

(d) Purchaser understands and acknowledges that:

(i) the Purchased Shares and Warrants have not been registered under the Securities Act or any
state securities laws and are being offered and sold in reliance upon specific exemptions from the
registration requirements of the Securities Act and state securities laws, and the Company is
relying upon the truth and accuracy of, and Purchaser’s compliance with, the representations,
warranties, covenants, agreements, acknowledgments and understandings of Purchaser contained in
this Agreement in order to determine the availability of such exemptions and the eligibility of
Purchaser to acquire the Securities;

(ii) the Securities must be held indefinitely unless a subsequent disposition thereof is
registered under the Securities Act or is exempt from such registration;

(iii) the Securities will bear a legend substantially in the form set forth in Section 5.1
herein; and

(iv) the Company will make a notation on its transfer books to such effect;

(e) the Company has made available to Purchaser all documents and information that the
Purchaser has requested relating to an investment in the Securities, and Purchaser has had an
opportunity to discuss this investment with representatives of the Company and ask questions of
them; and

(f) Purchaser has, in connection with its decision to purchase the Securities, relied solely
upon the representations and warranties of the Company contained in this Agreement.

4.4 Risk of Loss. Purchaser understands that its investment in the Securities involves a
significant degree of risk, including a risk of total loss of Purchaser’s investment, and Purchaser
has full cognizance of and understands all of the risk factors related to its purchase of the
Securities, including, but not limited to, those set forth in the Annual, Quarterly and Current
Reports filed by the Company with the Securities and Exchange Commission. Purchaser understands
that no representation is being made as to the future value of the Securities.

4.5 Confidentiality. Purchaser understands that this Agreement, the information contained in
all materials provided to Purchaser by the Company and its representatives, including any
information conveyed orally, in connection with the transactions contemplated hereunder
(“Confidential Information”), is strictly confidential and proprietary to the Company and
is being provided to Purchaser solely for Purchaser’s confidential use in connection with the
transactions contemplated hereunder. Purchaser agrees to use the Confidential Information solely
for the purpose of evaluating a possible investment in the Securities, and Purchaser acknowledges
that it is prohibited from distributing, divulging or discussing any Confidential Information, in
whole or in part, with any person, except Purchaser’s financial, investment or legal advisors (such
persons, “Authorized Advisors”), solely to the extent necessary for such Authorized Advisors to
assist Purchaser with its proposed investment in the Securities. To the extent that Purchaser
provides, directly or indirectly, any Confidential Information to any Authorized Advisor, Purchaser
shall (a) ensure that such Authorized Advisor maintain the confidentiality of the Confidential
Information to the same extent applicable to Purchaser as set forth in this Section 4.5 and
(b) be responsible for any breaches of this Section 4.5 by its Authorized Advisors.
Confidential Information does not include any information that is or becomes publicly available
through no fault of Purchaser, or that Purchaser is required to disclose pursuant to applicable
law, regulation or legal process; provided, however, that if Purchaser or any Authorized Advisor is
requested or ordered to disclose any Confidential Information pursuant to any court or other
government order or any other applicable legal procedure, it shall provide the Company with prompt
notice of any such requirement and the terms of and circumstances surrounding such requirement so
that the Company may seek an appropriate protective order or other remedy, or waive compliance with
the terms of this Section 4.5, and the Purchaser or such Authorized Advisor will provide
such cooperation, at Company’s expense, with respect to obtaining a protective order or other
remedy as the Company will request 

4.6 Brokers and Finders. The Purchaser has not employed any broker or finder or
incurred any liability for any brokerage fees, commissions or finders’ fees in connection with the
Sale or the other transactions contemplated by this Agreement.

Article 5

Miscellaneous

5.1 Legend. Each certificate that represents Securities shall have conspicuously
endorsed thereon the following legend:

THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS. THIS SECURITY MAY NOT BE
OFFERED OR TRANSFERRED BY SALE, ASSIGNMENT, PLEDGE OR OTHERWISE UNLESS (A) A
REGISTRATION STATEMENT FOR THE SECURITY UNDER THE SECURITIES ACT IS IN EFFECT OR (B)
THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL, WHICH OPINION IS SATISFACTORY TO THE
COMPANY, TO THE EFFECT THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES
ACT OR RELEVANT STATE SECURITIES LAWS.

5.2 Brokerage. Each party hereto will indemnify and hold harmless the other against
and in respect of any claim for brokerage or other commissions relative to this Agreement or to the
transactions contemplated hereby, based in any way on agreements, arrangements or understandings
made or claimed to have been made by such party with any third party.

5.3 Assignment; Parties in Interest. All representations, covenants and agreements
contained in this Agreement by or on behalf of any of the parties hereto shall bind and inure to
the benefit of the respective successors and assigns of the parties hereto whether so expressed or
not. Purchasers may not assign this Agreement without the Company’s prior written consent. This
Agreement is made solely for the benefit of and is binding upon each Purchaser and the Company, and
no other person shall acquire or have any right under or by virtue of this Agreement.

5.4 Notices. All notices, requests, consents, demands, and other communications under
this Agreement shall be in writing and shall be deemed to have been duly given on the date of
service if served personally on the party to whom notice is to be given, on the date of transmittal
of services via facsimile to the party to whom notice is to be given (with a confirming copy
delivered within 24 hours thereafter), or on the third day after mailing if mailed to the party to
whom notice is to be given, by first class mail, registered or certified, postage prepaid, or
overnight mail via a nationally recognized courier providing a receipt for delivery and properly
addressed as follows:

	 	 	 
	If to the Company:
	 	SafeStitch Medical, Inc.

4400 Biscayne Blvd.

Miami, FL 33137

Attn: James Martin, Chief Financial Officer

Fax: (305) 575-4130

	With a copy to:
	 	SafeStitch Medical, Inc.

4400 Biscayne Blvd.

Miami, FL 33137

Attn: Joshua Weingard, Chief Legal Officer

Fax: 305-575-4130

	If to the Purchaser:
	 	To the address specified on the signature page hereto.

Any party may change its address for purposes of this paragraph by giving notice of the new address
to each of the other parties in the manner set forth above.

5.5 Governing Law. This Agreement shall be governed by and construed in accordance
with the laws of the State of Florida for all purposes and in all respects, without regard to the
conflict of law provisions of such state that would cause the laws of another jurisdiction to
apply. The parties hereto acknowledge and agree that venue and jurisdiction for any claim, suit or
controversy related to or arising out of this Agreement shall lie in the state or federal courts
located in Miami-Dade County, Florida. THE PARTIES HEREBY WAIVE THE RIGHT TO JURY TRIAL OF ANY
MATTERS ARISING OUT OF THIS AGREEMENT OR THE CONDUCT OF THE RELATIONSHIP BETWEEN THEM.

5.6 Entire Agreement. This Agreement constitutes the sole and entire agreement of the
parties with respect to the subject matter hereof.

5.7 Counterparts. This Agreement may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same
instrument. Facsimile or other electronically scanned and transmitted signatures shall be deemed
originals for all purposes of this Agreement.

5.8 Amendments and Waivers. This Agreement may be amended or modified, and provisions
hereof may be waived, only with the written consent of the Company and each Purchaser.

5.9 Severability. If any provision of this Agreement shall be declared void or
unenforceable by any judicial or administrative authority, the validity of any other provision and
of the entire Agreement shall not be affected thereby.

5.10 Titles and Subtitles. The titles and subtitles used in this Agreement are for
convenience only and are not to be considered in construing or interpreting any term or provision
of this Agreement.

5.11 Liability Not Affected by Knowledge or Waiver. The right to recovery of losses
or other remedy based upon breach of representations, warranties or covenants will not be affected
by any investigation conducted, or knowledge acquired (or capable of being acquired) at any time,
whether before or after the execution and delivery of this Agreement, with respect to the accuracy
or inaccuracy of or compliance or noncompliance with any such representation, warranty, or
covenant.

[signature pages follow]

1

IN WITNESS WHEREOF, the undersigned have caused this Agreement to be executed by their
duly authorized representatives as of the date and year first above written.

SAFESTITCH MEDICAL, INC.

By:        Jeffrey G. Spragens      

Name: Jeffrey G. Spragens

Title: President and Chief Executive Officer

Company Signature Page to Securities Purchase Agreement

IN WITNESS WHEREOF, the undersigned have caused this Agreement to be executed by their duly
authorized representatives as of the date and year first above written.

	 	 	 
	 	 	PURCHASER(S):

	If a corporation or other entity:
	 	     

(name of corporation or entity)

By:     

Name:

	 	 	Title:

	If an individual:
	 	     

Name:

	 	 	     

(Name of co-purchaser, if any):

	Number of Purchased Shares:
	 	     

	Number of Warrants

(50% of Purchased Shares):
	 	     

	Contact Information:
	 	Address:

	 	 	     

     

     

     

Telephone:     

Facsimile:     

E-mail:     

	Social Security Number or Tax

Identification Number of the Registered

Holder listed above:
	 	     

Purchaser Signature Page to Securities Purchase Agreement

2

EXHIBIT A

WARRANT CERTIFICATE

$0.33 WARRANT

3

FORM OF COMMON STOCK WARRANT

THIS SECURITY AND THE SHARES (AS DEFINED BELOW) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY SHARE MAY BE SOLD
OR TRANSFERRED ABSENT SUCH REGISTRATION OR AN EXEMPTION THEREFROM.

Effective Date: March 22, 2013

WARRANT TO PURCHASE COMMON STOCK

SAFESTITCH MEDICAL, INC.

EXPIRING MARCH 22, 2018 (“EXPIRATION DATE”)

THIS WARRANT CERTIFIES THAT [ ] or their permitted assigns (“Holder”), for good and valuable
consideration, the receipt of which is hereby acknowledged, has been granted the right to purchase
from SafeStitch Medical, Inc., a Delaware corporation (the “Company”), at any time and from time to
time, for a period commencing on the Effective Date (as defined below) and ending on the Expiration
Date, [ ] (the “Warrant Number”) validly issued, fully-paid and non-assessable shares (the
“Shares”) of the Company’s common stock, par value $0.001 per share, subject to adjustment as
provided herein, at the exercise price of $0.33 per share (the “Exercise Price”).

	1.	 	Term of Warrant. Subject to the terms and conditions set forth herein, this Warrant shall be
exercisable, in whole or in part, during the term (“Term”) commencing at 9:00 a.m., New York,
New York time, on the date hereof (the “Effective Date”) and ending at 5:00 p.m., New York,
New York time on the Expiration Date, and shall be void thereafter.

	2.	 	Exercise of Warrant.

2.1. Manner of Exercise. The purchase rights represented by this Warrant are
exercisable by the Holder in whole or in part, at any time, or from time to time, during the Term,
by the surrender of this Warrant and the Notice of Exercise (in the form annexed hereto as Exhibit
A), duly completed and executed on behalf of the Holder, at the office of the Company (or such
other office or agency of the Company as it may designate by notice in writing to the Holder), upon
payment of the purchase price of the Shares to be purchased in cash or wire transfer to an account
designated by the Company.

2.2. Time of Exercise. This Warrant shall be deemed to have been exercised
immediately prior to the close of business on the date of its surrender for exercise as provided
above (the “Exercise Date”), and the Person entitled to receive the Shares issuable upon such
exercise shall be treated for all purposes as the holder of record of such Shares as of the close
of business on such date. As used in this Warrant, “Person” shall mean an individual, corporation,
limited liability company, partnership, trust, incorporated or unincorporated association, joint
venture, joint stock company, government (or any agency or political subdivision thereof) or other
entity of any kind.

2.3. Delivery of Certificate and Revised Warrant. As promptly as practicable on or
after the Exercise Date and in any event within fifteen (15) days thereafter, the Company at its
expense, will issue and deliver to the Person(s) entitled to receive the same a certificate or
certificates for the number of Shares issuable upon such exercise or other appropriate written
evidence of the issuance of the Shares. In the event that this Warrant is exercised in part, the
Company at its expense shall execute and deliver a new Warrant of like tenor exercisable for the
number of Shares for which this Warrant may then be exercised at the same time.

2.4. No Fractional Shares. No fractional Shares shall be issued upon the exercise of
this Warrant. In lieu of any fractional Share to which the Holder would otherwise be entitled, the
Company shall make a cash payment equal to the Exercise Price multiplied by such fraction.

	3.	 	Adjustments to the Shares.

3.1. Merger, Sale of Assets, etc. If at any time while this Warrant, or any portion
thereof, is outstanding and unexpired there shall be (i) a reorganization (other than a
combination, reclassification, exchange or subdivision of securities otherwise provided for
herein), (ii) a merger or consolidation of the Company with or into another entity in which the
Company is not the surviving entity, or a reverse triangular merger in which the Company is the
surviving entity but the Company’s shares of capital stock outstanding immediately prior to the
merger are converted by virtue of the merger into other property, whether in the form of
securities, cash or otherwise, or (iii) a sale or transfer of the Company’s properties and assets
as, or substantially as, an entirety to any other person, this Warrant shall thereafter represent
the right to acquire the number of Shares or other securities or property which the Holder of this
Warrant would have owned immediately after the consummation of such reorganization, merger,
consolidation, sale or transfer, if the Holder of this Warrant had exercised this Warrant
immediately before the effective date of the reorganization, merger, consolidation, sale or
transfer.

3.2. Reclassification, etc. If the Company, at any time while this Warrant, or any
portion hereof, remains outstanding and unexpired by reclassification of securities or otherwise,
shall change any of the securities as to which purchase rights under this Warrant exist into the
same or a different number of securities of any other class or classes, this Warrant shall
thereafter represent the right to acquire such number and kind of securities as would have been
issuable as the result of such change with respect to the securities that were subject to the
purchase rights under this Warrant immediately prior to such reclassification or other change and
the Warrant Number shall be appropriately adjusted, all subject to further adjustment as provided
for herein.

3.3. Split, Subdivision or Combination of Shares. If the Company at any time while
this Warrant, or any portion hereof, remains outstanding and unexpired shall split, subdivide or
combine the securities as to which purchase rights under this Warrant exist, into a different
number of securities of the same class, the Warrant Number shall be proportionately increased (and
the Exercise Price decreased correspondingly) in the case of a split or subdivision or
proportionately decreased (and the Exercise Price increased correspondingly) in the case of a
combination.

3.4. Adjustments for Dividends in Shares or Other Securities or Property. If while
this Warrant, or any portion hereof, remains outstanding and unexpired, the holders of the
securities as to which purchase rights under this Warrant exist at the time shall have received,
or, on or after the record date fixed for the determination of eligible shareholders, shall have
become entitled to receive, without payment therefor, other or additional securities or property
(other than cash) of the Company by way of dividend, then and in each case, this Warrant shall
represent the right to acquire, in addition to the number of Shares receivable upon exercise of
this Warrant, and without payment of any additional consideration therefor, the amount of such
other or additional securities or property (other than cash) of the Company that such Holder would
hold on the date of such exercise had it been the holder of record of the security receivable upon
exercise of this Warrant on the date hereof and had thereafter, during the period from the date
hereof to and including the date of such exercise, retained such Shares and/or all other additional
securities available to it as aforesaid during such period, giving effect to all adjustments called
for during such period by the provisions of this Warrant.

	4.	 	Certificate as to Adjustments. Upon the occurrence of each adjustment or readjustment
pursuant to Section 3, the Company at its expense shall promptly compute such adjustment or
readjustment in accordance with the terms hereof and furnish to each Holder a certificate
setting forth, in reasonable detail, the event requiring the adjustment or readjustment, the
amount of such adjustment or readjustment, the method by which such adjustment or readjustment
was calculated, the Exercise Price, and the number of Shares and the amount, if any, of other
property that at the time would be received upon the exercise of the Warrant. The Company
shall upon the written request, at any time, of any such Holder, furnish or cause to be
furnished to such Holder a like certificate.

	5.	 	Share Legend. Each certificate for Shares issued upon exercise of this Warrant shall bear
the following legend:

THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS. THIS SECURITY MAY NOT BE
OFFERED OR TRANSFERRED BY SALE, ASSIGNMENT, PLEDGE OR OTHERWISE UNLESS (A) A
REGISTRATION STATEMENT FOR THE SECURITY UNDER THE SECURITIES ACT IS IN EFFECT OR (B)
THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL, WHICH OPINION IS SATISFACTORY TO THE
COMPANY, TO THE EFFECT THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES
ACT OR RELEVANT STATE SECURITIES LAWS.

	6.	 	Shares to be Fully Paid. The Company will issue Shares pursuant to this Warrant as fully
paid, non-assessable and free from all liens and encumbrances.

	7.	 	Company to Reserve Shares. At all times before the Expiration Date, the Company will reserve
and keep available, free from preemptive rights, out of its authorized but unissued Shares or
Shares held in the treasury of the Company, for the purpose of effecting the exercise of this
Warrant, the full number of Shares then deliverable upon the exercise of this Warrant. The
issuance of this Warrant shall constitute full authority to those officers of the Company who
are charged with the duty of executing stock certificates to execute and issue the necessary
certificates for Shares upon exercise of this Warrant.

	8.	 	Exchange of Warrant. The Holder may exchange this Warrant, at the Company’s expense, at any
time prior to the Expiration Date, by surrendering this Warrant to the Company, for other
warrant certificates, upon the same terms and conditions of this Warrant, which in the
aggregate entitle the Holders to purchase the balance of Shares then covered by this Warrant.

	9.	 	No Rights as Stockholder. Except as otherwise provided herein, this Warrant will not entitle
the Holder to any of the rights of a stockholder of the Company, including, without
limitation, the right to vote or to receive distributions.

	10.	 	Amendment. This Warrant may not be amended except with the prior written consent of the
Holder and the Company. Any instrument given by or on behalf of the Holder in connection with
any consent to any modification or amendment will be conclusive and binding on all subsequent
holders of this Warrant.

	11.	 	Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt
by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or
mutilation of this Warrant or any stock certificate relating to the Shares, and in case of
loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in
the case of the Warrant, shall not include the posting of any bond), and upon surrender and
cancellation of such Warrant or stock certificate, if mutilated, the Company issue or cause to
be issued a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.

	12.	 	Transfer. The securities evidenced hereby have not been registered under the Securities Act
of 1933 or any state securities laws; such securities may not be transferred, sold, pledged,
or otherwise disposed of unless such securities are registered under the Securities Act of
1933 and such state laws or such transactions are exempt from the registration requirements
thereof. Upon surrender of this Warrant as a result of a transfer hereof, the Company, at the
expense of the transferee or transferor hereof, as the transferee and transferor may decide
between themselves, will issue and deliver to, or to the order of, the transferee a new
Warrant in the name of such transferee, or as such transferee (on payment by such transferee
of any applicable transfer taxes) may direct, calling in the aggregate on the face thereof for
the number of Shares called for on the face of this Warrant. As a condition to effecting any
transfer, the Holder shall notify the Company of the proposed transfer by delivering a Notice
of and Form of Assignment (in the form annexed hereto as Exhibit B), duly completed and
executed on behalf of the Holder at the office of the Company (or such other office or agency
of the Company as it may designate by notice in writing to the Holder).

	13.	 	Successors and Assigns. This Warrant shall not be assignable by the Company without the
prior written consent of the Holder and any such assignment in violation hereof shall be null
and void. Subject to the foregoing, this Warrant shall bind and inure to the benefit of the
Company and its permitted successors and assigns, the Holder and its successors and assigns.

	14.	 	Applicable Law. This Warrant shall be construed in accordance with, and governed by, the
laws of the State of Florida without giving effect to the conflict of law provisions thereof.

4

IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed as of the
Effective Date set forth above.

SAFESTITCH MEDICAL, INC.

(A DELAWARE corporation)

By:

Name: JEFFREY G. SPRAGENS

Title: CHIEF EXECUTIVE OFFICER AND PRESIDENT

(SIGNATURE PAGE FOR COMMON STOCK WARRANT)

5

EXHIBIT A

NOTICE OF EXERCISE

Dated:       

1. The undersigned hereby elects to purchase        shares of the common stock of
SafeStitch Medical, Inc. pursuant to the terms of the attached Warrant, and tenders herewith
payment of the purchase price of such securities in full. Such purchase price is being paid in
cash. .

2. Please issue certificate(s) representing said shares in the name of the undersigned or in such
other name(s) as is specified below and deliver such certificates to the address(es) specified
below:

[insert name(s) and address(es)]

3. Please issue a new Warrant for the unexercised portion of the attached Warrant in the name of
the undersigned or in such other name as is specified below:

[strike if not applicable]

[Insert name of Holder]

By:

Name:

Title:

6

EXHIBIT B

NOTICE OF AND

FORM OF ASSIGNMENT

(TO BE SIGNED ONLY ON TRANSFER OF WARRANT)

For value received, the undersigned hereby sells, assigns, and transfer unto       ,
federal taxpayer identification number       , whose address is       , the right
represented by the within Warrant to purchase        shares of Common Stock of        to
which the within Warrant relates, and appoints the Secretary of        Attorney to
transfer such right on the books of        with full power of substitution in the
premises.

	 	 	 
	Dated:

Signed in the presence of:

     
	 	     

(Signature must conform to name of holder as

specified on the face of the Warrant)

     

Address

7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}]]